Showing 181-190 of 1908 results for "".
Analyzing Safety Data From Level Up
https://practicaldermatology.com/series/the-practical-dermatology-podcast/analyzing-safety-data-from-level-up/33944/The latest news and updates, plus Matthew Zirwas, MD, FAAD, joins Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, to discuss the importance of the Week 16 safety data from the Level Up study on upadacitinib. Silverberg JI, Bunick CG, et al. Efficacy and safety of upadacitinib versuDermWireTV: Noble Educates on Self-Injection; AAD and DEF Meeting Updates
https://practicaldermatology.com/topics/practice-management/dermwiretv-noble-educates-on-self-injection-aad-and-def-meeting-updates/19645/Participants in a study by the company Noble show that the vast majority of patients—92%—would prefer to bring home a training device to practice with prior to starting self-injection. Noble creates trainers for autoinjectors intended to increase patient confidence and autonomy with self-managed treScientifically Speaking: The Truth About Skincare
https://practicaldermatology.com/series/scientifically-speaking/scientifically-speaking-the-truth-about-skincare/19876/From workhorse ingredients like antioxidants and retinol to newer molecules that address pigmentation and aging, there is a lot of noise in the skincare marketplace. And that's without talking about "natural" formulations. Joel L. Cohen, MD gets to the heart of the science, in a conversation with DeIntergenerational Dermatologists: A Family Tradition in All Respects
https://practicaldermatology.com/topics/general-topics/intergenerational-dermatologists-a-family-tradition-in-all-respects/23977/With Sandra Lee, MD, and Jeffrey Rebish, MD, By Heidi SpletePractice Pearls for PDT
https://practicaldermatology.com/series/pdt-in-practice/practice-pearls-for-pdt/20213/Jill S. Waibel, MD a Miami dermatologist specializing in laser surgery, cosmetic dermatology, and medical dermatology, discusses her background in the use of photodynamic therapy (PDT) and provides insight into off-label PDT treatments she provides her patients. Dr. Waibel is a world-recognized leadExosome Therapy: Explained
https://practicaldermatology.com/conferences/scale-2023/exosome-therapy-explained/20200/Jane Yoo, MD, explains exactly what exosomes are and highlights some current therapeutic uses for exosome therapy including treating hair loss and reducing redness after laser skin resurfacing.Eyeing a Treatment for Syringoma
https://practicaldermatology.com/series/scientifically-speaking/eyeing-a-treatment-for-syringoma/20112/Listen as Joel L. Cohen, MD describes early evidence for the use of nano pulse stimulation to treat syringoma, a notoriously challenging target.DermWireTV: Dupixent for Kids; Epsolay Launch; Scleroderma Awareness; Chicago Derms Celebrate Diversity
https://practicaldermatology.com/topics/practice-management/dermwiretv-dupixent-for-kids-epsolay-launch-scleroderma-awareness-chicago-derms-celebrate-diversity/20100/Epsolay (benzoyl peroxide 5%) Cream from Galderma is now available for the topical treatment of rosacea. It was developed by Sol-Gel. Dupixent from Sanofi and Regeneron is now the only biologic medicine FDA approved for use from infancy through adulthood for the management of atopic dermatitis. JuneScientifically Speaking: Optimizing Results with PRP
https://practicaldermatology.com/series/scientifically-speaking/scientifically-speaking-optimizing-results-with-prp/20034/As increasing evidence shows the benefits of PRP for hair loss, more practices are adding it to their menu. But the results of treatment can vary depending on numerous factors. Glynis Ablon, MD and Jeffrey Rapaport, MD talk to host Joel L. Cohen, MD about their approach and share expert tips to optiDermWireTV: Incyte's Opzelura, BMS Patient Week, Science of Skincare Summit
https://practicaldermatology.com/topics/psoriasis/dermwiretv-incytes-opzelura-bms-patient-week-science-of-skincare-summit/20003/Incyte’s Opzelura is the first topical JAK inhibitor approved in the US. Lawrence Eichenfield, MD weighs in on the cream formulation of ruxolitinib for treatment of mild-to-moderate atopic dermatitis in non-immunocompromised patients 12 years of age and older. Bristol Myers Squibb's seventh Global P